Ovarian cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BRCA1 20
• BRCA2 13
• PARP 27
• TP53 6
• PD-1 12
• AKT 2
• HER2 16
• PD-L1 7
• PI3K 3
• STAT3 1
• mTOR 0
• VEGF 6
• KRAS 6
• EGFR 3
• PTEN 2
• CTNNB1 0
• FAK 1
• MAPK 0
• MYC 0
• NRF2 0
• CTLA-4 6
• ERK 1
• JAK 0
• STING 0
• GPX4 0
• HIF-1 0
• MEK 1
• TROP2 4
• PALB2 5
• B7-H3 7
• CDK4/6 4
• ATM 1
• CD47 0
• IL-6 0
• EZH2 1
• JNK 0
• PIK3CA 3
• YAP 0
• BCL-2 0
• BRAF 4
• CXCR4 0
• HDAC 0
• PPAR 0
• AMPK 0
• ARID1A 3
• AXL 1
• COX-2 2
• NMDA 0
• TIGIT 0
• AR 0
• CD40 1
• HER3 1
• HMGB1 0
• KEAP1 1
• METTL3 0
• RAS 0
• TLR4 0
• FGFR 0
• PINK1 0
• PKM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 10,077 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Updated 5 Nov 2026

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Terminated

  AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

  NCT05617755· Arsenal Biosciences, Inc.· Updated 29 Oct 2026

  “Active patients have been rolled over to a separate LTFU study.”Registry text, quoted unchanged. Source

• Terminated

  huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

  NCT05057715· University of Pennsylvania· Updated 29 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  PRO1107 in Patients With Advanced Solid Tumors

  NCT06171789· Genmab· Updated 29 Oct 2026

  “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

  NCT07030907· Outpace Bio, Inc.· Updated 26 Oct 2026

  “Business decision”Registry text, quoted unchanged. Source

• Withdrawn

  A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

  NCT05479045· Georgetown University· Updated 9 Oct 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Terminated

  Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer

  NCT05833321· Centre Hospitalier Metropole Savoie· Updated 8 Oct 2026

  “recruitement failure”Registry text, quoted unchanged. Source

• Suspended

  Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

  NCT05866679· M.D. Anderson Cancer Center· Updated 6 Oct 2026

  “Suspension”Registry text, quoted unchanged. Source

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Updated 22 Sept 2026

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”Registry text, quoted unchanged. Source

• Suspended

  Using Aspirin to Improve Immunological Features of Ovarian Tumors

  NCT05080946· H. Lee Moffitt Cancer Center and Research Institute· Updated 15 Sept 2026

  “Study drug is expiring. Will reopen when new drug is received.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors

  NCT06660654· Daiichi Sankyo Inc.· Source

• Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  NCT07851025· AstraZeneca· Source

• Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  NCT06787612· Regeneron Pharmaceuticals· Source

• The Vanguard Study: Testing a New Way to Screen for Cancer

  NCT06995898· National Cancer Institute (NCI)· Source

• Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  NCT01950572· National Cancer Institute (NCI)· Source

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  NCT01174121· National Cancer Institute (NCI)· Source

• A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

  NCT07776691· Merck Sharp & Dohme LLC· Source

• Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

  NCT07504588· National Cancer Institute (NCI)· Source

• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

  NCT04847063· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 48
• Organoids 19
• Mendelian Randomization Analysis 28
• CRISPR-Cas Systems 15
• Gene Expression Profiling 126
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 6
• Exome Sequencing 11
• Proteomics 62
• Metabolomics 17
• Mass Spectrometry 6
• Flow Cytometry 26
• Immunohistochemistry 95
• Liquid Biopsy 15
• Circulating Tumor DNA 13
• Xenograft Model Antitumor Assays 234
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 56
• Machine Learning 58
• Deep Learning 35
• Cohort Studies 104
• Genome-Wide Association Study 25

See which targets of this disease your abstract mentions, and go to the people working on them.